Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway

Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway

Abstract Background  Type 2 diabetes (T2D) is an independent risk factor for Alzheimer's disease (AD). Exendin-4 (Ex-4), a widely used glucagon-like peptide-1 receptor agonist drug in the treatment of T2D, has been demonstrated the therapeutic effects on diabetic encephalopathy (DE). Especially...

Full description

Bibliographic Details
Main Authors: Xiaonan Kang, Dan Wang, Lu Zhang, Teng Huang, Siyue Liu, Xiaohui Feng, Yaoyao Guo, Ziyin Zhang, Zhongjing Wang, Huihui Ren, Gang Yuan
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Molecular Medicine
Subjects:
Type 2 diabetes
Cognitive impairment
Tau hyperphosphorylation
Glucagon-like peptide-1 receptor agonist
Wnt/β-catenin pathway
NeuroD1
Online Access:https://doi.org/10.1186/s10020-023-00718-2

Internet

https://doi.org/10.1186/s10020-023-00718-2

Similar Items